Phase I/II (AM1030-CREAM)
Second SAD group (2:3) completed.
Third, and final, SAD group to be started w/c January 26.
• AMAP102 falls short of primary endpoint in exploratory Phase 2a study
• Subgroup analyses expected to confirm AMAP102’s therapeutic potential
• AnaMar’s 5-HT receptor targeting platform continues to build momentum